Vivos Therapeutics (VVOS) Preferred Stock Liabilities (2019)
Vivos Therapeutics has reported Preferred Stock Liabilities over the past 1 years, most recently at $1.3 million for Q4 2019.
- Quarterly Preferred Stock Liabilities changed N/A to $1.3 million in Q4 2019 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Dec 2019, changed N/A year-over-year, with the annual reading at $1.3 million for FY2019, N/A changed from the prior year.
- Preferred Stock Liabilities was $1.3 million for Q4 2019 at Vivos Therapeutics.
- Over five years, Preferred Stock Liabilities peaked at $1.3 million in Q4 2019 and troughed at $1.3 million in Q4 2019.